Eisai Begins Rolling BLA Submission of Lecanemab for Early Alzheimer Disease
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
Alzheimer Disease
Donanemab Granted Breakthrough Tx Status for Alzheimer Disease
Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
Lecanemab Gets Breakthrough Tx Status for Alzheimer Disease
Lecanemab (BAN2401) is an investigational anti-amyloid beta protofibril antibody
for the treatment of Alzheimer disease.
Gene Therapy Fast Tracked for APOE4-Associated Alzheimer Disease
The investigational adeno-associated virus mediated gene therapy is being developed to deliver the protective APOE2 gene to the CNS.
Alzheimer Disease Tied to Adverse Financial Events
Adverse financial events seen years before diagnosis and become more prevalent after diagnosis
Individuals With a High Genetic Risk for Alzheimer’s Disease Have Altered Sleep Patterns
Is there a causal relationship between depressive disorders and late-life neurodegenerative diseases? Or, is their co-occurrence due to confounding or common risk factors, such as aging?
The Lancet Commission Identifies Additional Dementia Risk Factors
The Lancet Commission added 3 new risk factors for dementia that coupled with the previous 9 lifestyle risk factors might prevent or delay up to 40% of dementias worldwide.
Poor Dental Health May Increase Risk for Incident Dementia, MCI
Individuals with severe periodontal disease or edentulism have an increased risk for incident dementia.
Novel Therapy for Alzheimer Disease Agitation Gets Breakthrough Designation
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease (AD) agitation.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...